| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185489 | Gynecologic Oncology | 2013 | 6 Pages |
Abstract
Sorafenib 400Â mg BID cannot be recommended as maintenance therapy for patients with OC in complete remission. Assessment of efficacy was limited by the high rate of dose reductions and early discontinuations.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Thomas J. Herzog, Giovanni Scambia, Byoung-Gie Kim, Catherine Lhommé, Janina Markowska, Isabelle Ray-Coquard, Jalid Sehouli, Nicoletta Colombo, Minghua Shan, Oana Petrenciuc, Amit Oza,